missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human TALDO1 (aa 189-263) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (97%), Rat (97%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-65496 (PA5-65496. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Transaldolase 1 is a key enzyme of the nonoxidative pentose phosphate pathway providing ribose-5-phosphate for nucleic acid synthesis and NADPH for lipid biosynthesis. This pathway can also maintain glutathione at a reduced state and thus protect sulfhydryl groups and cellular integrity from oxygen radicals. The functional gene of transaldolase 1 is located on chromosome 11 and a pseudogene is identified on chromosome 1 but there are conflicting map locations. The second and third exon of this gene were developed by insertion of a retrotransposable element. This gene is thought to be involved in multiple sclerosis.
Specifications
Specifications
| Accession Number | P37837 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 6888 |
| Name | Human TALDO1 (aa 189-263) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | dihydroxyacetone transferase; glycerone transferase; TAL; TALDO; TALDO1; TALDOR; TALH; TAL-H; testicular secretory protein Li 56; transaldolase; transaldolase 1 |
| Common Name | TALDO1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction